Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Samantha B. Kemp, Noah Cheng, Nune Markosyan, et al.
Cancer Discovery (2022) Vol. 13, Iss. 2, pp. 298-311
Open Access | Times Cited: 220

Showing 26-50 of 220 citing articles:

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Significance of Cancer-Associated Fibroblasts in the Interactions of Cancer Cells with the Tumor Microenvironment of Heterogeneous Tumor Tissue
Yoshimi Arima, Satoko Matsueda, Hideyuki Saya
Cancers (2023) Vol. 15, Iss. 9, pp. 2536-2536
Open Access | Times Cited: 24
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Recent advances in drug delivery and targeting for the treatment of pancreatic cancer
Nilkamal Pramanik, Aditya K. Gupta, Yashwardhan Ghanwatkar, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 231-260
Closed Access | Times Cited: 13
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
Il‐Kyu Kim, Mark S. Diamond, Salina Yuan, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer
Loretah Chibaya, Kelly D. DeMarco, Christina F. Lusi, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 762
Open Access | Times Cited: 12
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth
Katelyn L. Donahue, Hannah R. Watkoske, Padma Kadiyala, et al.
Cancer Discovery (2024) Vol. 14, Iss. 10, pp. 1964-1989
Open Access | Times Cited: 11
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
Metabolic adaptations in cancer stem cells: A key to therapy resistance
Matthew Masoudi, Dilpreet Moti, Raha Masoudi, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 5, pp. 167164-167164
Closed Access | Times Cited: 10
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives
Christos Adamopoulos, Donatella Delle Cave, Athanasios G. Papavassiliou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1631-1631
Open Access | Times Cited: 9
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Anupriya Singhal, Hannah C. Styers, Jonathan Rub, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2122-2134
Closed Access | Times Cited: 9
Overcoming therapy resistance in pancreatic cancer: New insights and future directions
Margarita Espona‐Fiedler, Cédric Patthey, Stina Lindblad, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116492-116492
Open Access | Times Cited: 8
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
Adel Shahnam, Alexander Davis, Lauren Brown, et al.
Lung Cancer (2025) Vol. 201, pp. 108421-108421
Closed Access | Times Cited: 1
The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy
Marc Hilmi, Matthieu Delaye, Milena Muzzolini, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 12, pp. 1129-1142
Closed Access | Times Cited: 21
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun‐Hao Pan, et al.
Cancer Discovery (2023) Vol. 14, Iss. 2, pp. 308-325
Open Access | Times Cited: 19
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai
Cells (2024) Vol. 13, Iss. 7, pp. 602-602
Open Access | Times Cited: 7
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
Rui Zheng, Xiaobin Liu, Yufu Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7

Scroll to top